Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to progressive and irreversible loss of visual function. Geographic atrophy is defined by the presence of sharply demarcated atrophic lesions of the outer retina, resulting from loss of photoreceptors, retinal pigment epithelium (RPE), and underlying choriocapillaris. These lesions typically appear first in the perifoveal macula, initially sparing the foveal center, and over time often expand and coalesce to include the fovea. Although the kinetics of GA progression are highly variable among individual patients, a growing body of evidence suggests that specific characteristics may be important in predicting disease progression and outcomes. This review synthesizes current understanding of GA progression in AMD and the factors known or postulated to be relevant to GA lesion enlargement, including both affected and fellow eye characteristics. In addition, the roles of genetic, environmental, and demographic factors in GA lesion enlargement are discussed. Overall, GA progression rates reported in the literature for total study populations range from 0.53 to 2.6 mm 2 /year (median, w1.78 mm 2 /year), assessed primarily by color fundus photography or fundus autofluorescence (FAF) imaging. Several factors that could inform an individual's disease prognosis have been replicated in multiple cohorts: baseline lesion size, lesion location, multifocality, FAF patterns, and fellow eye status. Because best-corrected visual acuity does not correspond directly to GA lesion enlargement due to possible foveal sparing, alternative assessments are being explored to capture the relationship between anatomic progression and visual function decline, including microperimetry, low-luminance visual acuity, reading speed assessments, and patient-reported outcomes. Understanding GA progression and its individual variability is critical in the design of clinical studies, in the interpretation and application of clinical trial results, and for counseling patients on how disease progression may affect their individual prognosis. Supplemental material available at www.aaojournal.org.
Geographic atrophy (GA) is an advanced form of agerelated macular degeneration (AMD), characterized by progressive and irreversible loss of photoreceptors, retinal pigment epithelium (RPE), and choriocapillaris. 1, 2 Although atrophic lesions typically appear first in the perifoveal macula, sparing the foveal center, over time these lesions often expand and coalesce to include the fovea. Both the rate and the nature of GA progression are highly variable among individual patients, and evidence suggests specific characteristics may be important in predicting GA lesion enlargement.
Geographic atrophy is estimated to affect approximately 5 million globally, and its prevalence increases exponentially with age. 3, 4 Geographic atrophy is typically bilateral, 5 and lesion occurrence and enlargement result in irreversible visual function loss. Perifoveal atrophy affects visual performance, including reading, driving, and low-light vision, 6e8 whereas foveal involvement may profoundly affect central visual acuity (VA). 5 To date, there are no approved treatments to reverse, prevent, or reduce the rate of GA progression, although several potential therapies are in clinical trials. Understanding GA progression and the interindividual and intraindividual disease variability is critical for clinical trial design, interpretation and application of trial results, and counseling patients and caregivers regarding the prognosis and potential impact of GA progression on quality of life.
In this review, we synthesize the current understanding of GA progression and factors that are potentially prognostic for disease progression. We begin by reviewing methodology for identifying and monitoring GA, and summarize GA progression findings from observational and interventional studies. Subsequently, anatomic, genetic, and other potential factors associated with disease progression are discussed. Finally, we discuss the impact of GA progression on visual function.
Defining Geographic Atrophy
Geographic atrophy secondary to AMD is currently defined by the presence of sharply demarcated atrophic lesions of the outer retina, resulting from loss of photoreceptors, RPE, and underlying choriocapillaris, leading to irreversible loss of visual function. Geographic atrophy lesions are directly visualized by multiple imaging modalities 9e16 (Fig 1) , identified by specific features in each, including increased visibility of underlying choroidal vessels with a sharpedged border (color fundus photography [CFP]), lack of lipofuscin autofluorescence (fundus autofluorescence [FAF] ), and light hypertransmission through retinal layers OCT. Recently, the Classification of Atrophy Meetings group recommended that non-neovascular AMD trials include CFP, FAF, near-infrared reflectance (NIR), and spectral-domain or swept-source OCT. 15 These and other modalities for visualizing GA are discussed next. Tables 1 and 2 24, 25 An eye may have 1 (unifocal) or multiple (multifocal) atrophic lesions, which when summed determine the total lesion area.
The change in total GA lesion area over time (e.g., millimeters squared per year) is currently the most frequently used and accepted endpoint for assessing GA progression and efficacy of therapeutic interventions in clinical trials, 16 most of which aim to reduce the lesion enlargement rate.
Color Fundus Photography
By CFP, GA lesions are defined as sharply demarcated areas of RPE hypopigmentation, with clear visibility of underlying choroidal vessels. The historical standard for imaging GA, CFP was the primary modality of large epidemiologic studies and disease classification systems. However, CFP cannot visualize many lesion characteristics associated with GA progression.
Fundus Autofluorescence
By FAF (short-wavelength), GA lesions appear as areas of decreased autofluorescence (hypoautofluorescence) due to loss of RPE cells containing intrinsic fluorophores such as lipofuscin. Fundus autofluorescence imaging using a blue excitation wavelength (488 nm) and confocal scanning laser ophthalmoscopy is the predominant modality for assessing GA lesion size and progression, and is the modality currently accepted by regulators, for example, the European Figure 1 . Multimodal imaging of geographic atrophy (GA). Example images of GA from 1 eye using color fundus photography (CFP), fundus autofluorescence (FAF), fluorescein angiography (FA), near-infrared reflectance (NIR), and spectral-domain OCT. Scale bars ¼ 500 mm.
Medicines Agency and U.S. Food and Drug Administration, for clinical trials. Flood-illuminated and green-wavelength widefield FAF systems also are available. Geographic atrophy lesions on FAF are also characterized by abnormal patterns of hyperautofluorescence surrounding the atrophic regions. 26 Typically, FAF signals are "definitely decreased" in areas of GA, although some lesions may also present with "probable or questionable decreased FAF" as is particularly seen with the diffuse-trickling FAF phenotype (an example of this appears in Fig 5A, patient no. 3) . 27 Also, as the fovea appears darker than surrounding areas in a healthy retina from normal luteal pigment, evaluating foveal integrity in the presence of GA by short-wavelength FAF alone may be challenging. 28 In these cases, adjunctive use of other imaging modalities such as NIR and OCT can be instrumental in confirming lesion boundaries.
Near-Infrared Reflectance
Near-infrared reflectance imaging uses near-infrared wavelengths (787e820 nm), longer than FAF, which are minimally absorbed by media opacities, neurosensory layers, and macular luteal pigments. Geographic atrophy lesions on NIR usually appear brighter than nonatrophic regions, and NIR can aid in detecting foveal lesion boundaries, where image contrast appears lower on FAF.
28e30 However, subfoveal choroidal thickness can also influence NIR intensity and may introduce variability over images. 31 
Near-Infrared Autofluorescence
By near-infrared autofluorescence, atrophic areas appear hypoautofluorescent from the lack of melanin, which is autofluorescent in the infrared spectrum and enriched in RPE cells. 32 Similar to NIR, advantages of near-infrared autofluorescence include that it is unaffected by luteal pigment, although commercial near-infrared autofluorescence devices were recently discontinued. Eyes with dark irides also have strong autofluorescence from underlying choroidal melanocytes, and therefore this signal may "wash out" areas of RPE cell loss that would otherwise appear hypoautofluorescent, 32 making atrophy borders difficult to identify.
Fluorescein Angiography
By fluorescein angiography, GA lesions are identified as well-defined areas of early hyperfluorescence termed "window defects," created when RPE loss enhances visualization of underlying choroidal vasculature perfused with intravascular fluorescein dye. Late staining of surrounding choroidal stromal tissue may blur GA margins in later phases of fluorescein angiography, rendering its detection less precise.
OCT
By OCT, GA lesions are generally identified by the loss of outer retinal layers corresponding to the RPE and photoreceptors. However, consensus in demarcating lesion boundaries on OCT has not yet been reached, in part because numerous distinct lesion features are visible on both crosssectional and en face OCT compared with purely en face modalities, including CFP and FAF. For example, "nascent GA," a drusen-associated atrophy preceding development of complete outer retinal atrophy, was identified on OCT by subsidence of the outer plexiform layer and inner nuclear layer, and a wedge-shaped band within the outer plexiform layer. 33 The GA lesion boundaries on OCT have been defined by an abrupt increase in choroidal reflectivity below Bruch's membrane from loss of absorbing outer retinal structures and RPE (choroidal hypertransmission); RPE, photoreceptor, and choriocapillaris layer loss; and external limiting membrane absence/descent. 12, 14, 34, 35 In addition to resolving fine retinal details, spectraldomain OCT is widely available and comfortable for patients, whereas newer swept-source OCT devices have faster acquisition and use longer wavelengths with better tissue penetration. 15 Consequently, OCT, for both cross-sectional and en face imaging, is emerging as a preferred modality to assess GA lesion features. Compared with FAF or CFP, to date fewer studies have used OCT to define GA borders or measure progression.
OCT Angiography
OCT angiography detects blood flow by analyzing changes in tissue reflectivity occurring between rapidly acquired images, enabling 3-dimensional reconstruction of retinal and choroidal vasculature. Absence of choriocapillaris flow within a GA lesion has been reported with OCT angiography.
36e38 Alterations in choriocapillaris flow outside the GA lesion are also apparent in some eyes with GA. 36, 37 However, short interscan intervals could make choriocapillaris flow reductions appear as choriocapillaris loss.
36,39

Multicolor Confocal Scanning Laser Ophthalmoscopy
Multicolor images are composite images acquired by simultaneous confocal scanning lasers of blue, green, and red/near-infrared wavelengths, which penetrate retinal layers at different depths: inner retinaevitreoretinal interface, retinal blood vessels/intraretinal features, and outer retina/ choroid, respectively. 40 The GA lesion boundaries may be more readily identified with multicolor images than CFP 9 and with less interference from media opacities. 40 
Methods
Studies reporting on GA progression (Table 2 ) and factors associated with GA progression (Tables 3 and 4) were identified via a PubMed literature search using the terms "geographic atrophy," "atrophy," "macular degeneration," "progression," "enlargement," and "growth," and sorted for relevance (detailed Supplemental Methods are available at www.aaojournal.org). Table 2 inclusion also required reporting of lesion enlargement rate; studies were excluded if they had 15 patients, identified patients retrospectively, did not report on an all-comers population, or were subanalyses of an included study. Studies are plotted in Figure 2A if baseline lesion size and progression rate were reported.
Geographic Atrophy Progression and Prognostic Factors
Overall, GA progression rates reported in the literature for total study populations range from 0.53 41 to 2.6 42 mm 2 /year (median, w1.78 mm 2 /year; Table 2 , Fig 2A) . Within a study, GA progression rates demonstrate both interindividual and intraindividual variability (Fig 2B) . Factors potentially prognostic for an individual's progression rate include lesion features in affected (Fig 3) and fellow eyes (Fig 4) ; genetic, environmental, and demographic factors may also contribute (Table 3 ).
An individual's prior progression rate is prognostic for his/her future progression rate. 42 Modeling progression in the Age-Related Eye Disease Study (AREDS) for baseline lesion sizes of !0.5 disc area (DA) (defined as !1.33 mm 2 ) 5 resulted in a linear model of lesion growth.
5
Lesion Features and Specific Characteristics of the Affected Eye
Lesion Size
Baseline GA lesion size ( Fig 3A) is consistently associated with progression; smaller baseline lesion size is associated with lower progression rates. 26 However, it is unclear whether the association between baseline lesion size and progression rate is prognostic for an individual's disease progression or reflects heterogeneity of disease severity within a study, in which individual baseline lesion sizes range from <1 to >40 mm 2 .
5,43,46
Studies may report progression rates normalized for baseline lesion size, using the square-root transformation or other mathematical strategies. 47 When applied to the AREDS data set, the association between baseline lesion size and progression rate was no longer significant. 47 
Lesion Focality and Configuration
Eyes with multifocal lesions (Fig 3A) respectively). 13,48e54 In the observational study by Sunness et al, 43 eyes starting with unifocal lesions and progressing to multifocal, horseshoe, ring, or solid configurations had greater GA progression rates than eyes with a stable The 2 eculizumab treatment groups were pooled for analysis (n ¼ 10 each), receiving either eculizumab (group 1) 600 mg or (group 2) 900 mg weekly for 4 weeks, followed by (group 1) 900 mg or (group 2) 1200 mg every 2 weeks until week 24.
{ Lesion size change from baseline at 12 months; annualized GA progression rate through 18 months (or early exit) not reported. configuration. To quantify this, a GA circularity index (GACI) was proposed based on GA lesion perimeter and deviation from circularity. 51 Eyes with the lowest GACI (i.e., lesions deviating most from a circle) were generally multifocal and had higher progression rates versus eyes with higher GACI (square-root transformation, GACI <0.25 vs. >0.75: 0.40 vs. 0.21 mm/year; P < 0.001). 51 
Lesion Location
Extrafoveal GA lesions progress faster than foveal lesions ( Figs 3A, 5B ). In the Geographic Atrophy Progression study, extrafoveal versus foveal (300-mm diameter foveal-centered circle) lesions progressed at significantly greater rates (2.05 vs. 1.28 mm 2 /year, respectively; P ¼ 0.001). 13 An analysis of directional progression kinetics among FAM study patients with baseline foveal sparing also revealed that lesion progression toward the periphery was 2.8-fold faster than progression toward the fovea (square-root transformation: 0.319 vs. 0.116 mm/year, respectively). 28 Geographic atrophy lesions may grow into fovealsurrounding horseshoe or ring shapes. 43 The progression of GA from first appearance to foveal center involvement has been reported to occur over 2.5 years (median), 5 although patients may have foveal GA at initial diagnosis. 5, 48 Among other hypotheses, it was speculated that preferential foveal sparing reflects the relatively lower susceptibility of cone versus rod photoreceptors to cell death.
64,65
Fundus Autofluorescence Patterns
In most eyes, the dark, hypoautofluorescent patches signifying GA lesions are surrounded by varying degrees of hyperautofluorescence, particularly at junctional regions of atrophy. Because hyperautofluorescence can indicate lipofuscin density, it has been hypothesized that excessive lipofuscin accumulation contributes to GA pathogenesis. 66 Alternatively, histologic studies suggest hyperautofluorescence reflects a clumping or vertical stacking of fluorophore-containing cells, and FAF patterns may reflect disorganization of cellular layers.
67,68
The FAM study investigated the correlation between FAF hyperautofluorescence patterns and GA progression rates as its primary objective. 26 The FAF patterns ( Fig 3A) were classified as none, focal, banded, patchy, or diffuse; diffuse patterns were further categorized as reticular, branching, fine-granular, fine-granular with peripheral punctate spots, or trickling. 26 At baseline, more than half of eyes displayed diffuse FAF patterns. The GA progression rate was associated with FAF patterns, with the lowest observed in eyes with no or focal patterns and the highest with banded or diffuse patterns (median, 0.38, 0.81, 1.81, 1.77 mm 2 / year, respectively; none þ focal vs. banded þ diffuse, P < 0.0001). Eyes with the diffuse-trickling pattern represented a subgroup with particularly rapid progression (median, 3.02 mm 2 /year). 26 This relationship between FAF patterns and GA progression rate has been replicated to some extent in other cohorts. 13, 41, 45, 52 The Characterization of Geographic Atrophy Progression in Patients with Age-related Macular Degeneration (GAIN) study reported that FAF patterns are associated with the GA progression rate, but also with baseline lesion size and follow-up duration. 44 Eyes with a focal pattern or no FAF changes had smaller baseline GA areas than eyes with banded or diffuse patterns. The authors speculated that FAF patterns reflect disease severity or duration and may evolve from no FAF changes or focal pattern to diffuse or banded patterns. 44 Whether there is a spatial correlation between FAF patterns and future location of GA lesion development or extension is currently unclear. 26, 66, 69 Further longitudinal studies following an individual's FAF pattern over time are needed to elucidate the relationship between FAF patterns and GA progression. Table 2 , plotted against baseline lesion size. When available, mean values were selected over median values. If not provided in the reference, annualized GA enlargement rates were calculated from the available values (e.g., derived the 1-year from a 2-year rate). For interventional trials, the sham/placebo/vehicle arms are plotted. B, Rates of GA progression from individuals from the natural history study by Sunness et al. 42 Inset box shows the range of average values from (A); note the variability in individual enlargement rates and how enlargement rates for most individuals fall outside of the average range. Reprinted from Ophthalmology, Sunness et al, 42 " 
Extent of Abnormal Fundus Autofluorescence
Geographic atrophy progression rates have been positively correlated with the extent of hyperautofluorescence surrounding the lesion, defined as rim-area focal hyperfluorescence 70, 71 or as the convex hull (convex polygon outlining the increased FAF area surrounding the lesion) (Fig 3A) . 72 
Junctional Zone Features
Structural abnormalities at the junctional zone of atrophy on OCT, including irregular RPE elevations, 52 splitting of the band corresponding to the RPEeBruch's membrane complex, 52 and increased inner nuclear layer thickness, 73 are associated with faster progression rates compared with lesions with smooth margins (Fig 3B) . Splitting of the RPEeBruch's membrane complex band is also seen in eyes with the rapid-progressing diffuse-trickling phenotype seen on FAF. 27 These features correlate with hyperautofluorescent areas on FAF 74 and may reflect the presence of excessive basal laminar deposits detectable once a critical vertical extension of extracellular material is reached. 27 
OCT Minimum Intensity
Minimum intensity is the lowest image intensity from each A-scan from the sub-RPE slab region. Excluding the fovea, minimum intensity values were significantly higher in areas of lesion growth and correlated with overall progression rate. Areas of increased minimum intensity corresponded to Figure 4 . Fellow eye features associated with geographic atrophy (GA) progression rate in the affected eye. Fundus autofluorescence and OCT images from left and right eyes of the same patient. Top, Bilateral GA; both eyes are at risk for a relatively higher rate of GA lesion progression. Bottom, Geographic atrophy in the affected eye (left) and intermediate age-related macular degeneration (AMD) in the fellow eye (right); the affected eye is at risk for a relatively lower rate of GA lesion progression. Figure 5 . Progression of geographic atrophy (GA). A, Fundus autofluorescence (FAF) images from 3 patients presenting with different lesion types and their GA lesion progression rates from baseline to follow-up. B, Projected directional spread of atrophy; note greater spread of atrophy in the periphery than toward the center. 28 C, The diagram drafts the potential impact of interventions that reduce overall GA progression on total GA area and on the relatively longer preservation of the spared fovea (foveal island area). Table 3 
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hyperreflectivity, or atrophy, of the outer nuclear/Henle fiber layers on cross-sectional scans. 63 
Ellipsoid Zone Disruption
The area of ellipsoid zone disruption on OCT may predict the location of future GA progression, but not progression rate. 81 In a study assessing the ellipsoid zone using en face OCT, 43% of eyes demonstrated a pattern of disruption outside the baseline GA lesion that predicted the 1-year location of GA progression. 62 
Outer Retinal Tubulations
Outer retinal tubulations (Fig 3B) are branching tubular structures in the outer nuclear layer oriented parallel to en face OCT scans, appearing as circles on cross-sectional scans.
82e84 Composed of surviving cone photoreceptors enclosed by Müller glial processes, outer retinal tubulations are a degenerative response to outer retinal injury in areas of RPE loss. 82e84 The presence 52 and absence 85 of outer retinal tubulations were both reported with greater GA enlargement rates; the reason for this conflict is unclear and requires further study.
Choroidal Thickness
In a small cohort, reduced subfoveal choroidal thickness correlated with higher progression rates. 86 In addition, the fast-progressing diffuse-trickling FAF pattern demonstrates a significantly thinner choroid than nondiffuse-trickling phenotypes. 87 Overall, eyes with GA have reduced subfoveal choroidal thickness compared with age-matched healthy eyes, 87e89 although one study reported this reduction was limited to the group of eyes with reticular pseudodrusen. 89 
Vitreoretinal Traction
Vitreoretinal traction (Fig 3B) on OCT is associated with GA progression (presence vs. absence, 2.99 vs. 1.45 mm 2 /year; P < 0.001). 59 Mechanical stress of vitreoretinal traction may affect the natural history of GA; structural distortion of the RPE layer has been hypothesized. 59 
Reticular Pseudodrusen
Eyes with GA have a high prevalence of reticular pseudodrusen (Fig 3B) , 47,90e92 which correlate with subretinal drusenoid deposits anterior to the RPE layer on OCT and histopathology. 93, 94 Their presence strongly associates with the progression of intermediate AMD to GA, 50,92,95e97 but might not correlate with GA lesion progression rates. 98 Reticular pseudodrusen regression is associated with outer retinal atrophy development in some eyes 99 and may predict future locations of GA development. 47, 53 Reticular pseudodrusen are also associated with the development of multifocal lesion configurations, 47, 53 which progress faster than unifocal configurations. 13e15,20,21,24e26 Genetic factors/single nucleotide polymorphisms (Continued)
Some patient cohorts were analyzed in multiple publications, as noted in the Significance not calculated; no statistics provided in publication.
Fellow Eye Characteristics
The presence of GA in 1 eye is a strong predictor of future GA in the second eye. In AREDS, the median time from unilateral to bilateral GA was estimated at 7 years. 5 Overall, intereye progression rates are highly correlated among patients with bilateral GA, although there is some individual variability. 5, 42, 43, 100 Fellow-eye disease status also associates with progression; GA progresses at greater rates when the fellow eye has GA (bilateral GA), lower rates when the fellow eye has early/intermediate AMD, and intermediate rates when the fellow eye has choroidal neovascularization. 42, 78, 101 Genetic, Environmental, and Demographic Factors Although many studies have identified genetic, environmental, and demographic characteristics associated with GA development, evidence for their effect on GA progression is sparse. No consistent demographic or environmental factors have been linked to GA progression rate, including age, gender, hypertension, or diabetes (Table 3) . Smoking status predicted faster GA progression in the Blue Mountains Eye Study 49 and Multicenter Group on AMD 61 cohorts, but not in FAM 26 or AREDS. 5 Different findings among studies may reflect the patient populations, cohort size, or variable collection and analysis methods.
There is strong evidence for a role for genetics in the development of advanced AMD. 102, 103 The largest genome-wide association study to date identified 52 variants in 34 loci involved in the complement cascade, lipid metabolism, extracellular matrix remodeling, and other pathways, nearly all of which confer a similar risk of neovascular AMD and GA. 75 In contrast, no single nucleotide polymorphism examined has been consistently linked to GA progression rate (Table 3) . Of note, ARMS2_rs10490924 was significantly associated with increased GA progression in the AREDS 77 and AREDS þ FAM 78 combined cohorts, but not in the FAM cohort alone. 78, 79 Single nucleotide polymorphisms in C3, 78 CFH, 50,61 CFI, 56 and CFB 61 have also been linked to GA progression, but the results have not been replicated. Additional large studies with appropriate controls for potential confounders are needed to confirm these findings. To this end, several ongoing interventional and observational studies are prospectively evaluating potential effects of genetic factors on GA progression. 104 
Geographic Atrophy Progression and Visual Function
Although GA lesion enlargement is the most widely used and reproducible assessment of GA progression, it also correlates with visual function decline and thus disease severity. Best-corrected VA (BCVA), the standard vision assessment, often underrepresents functional deficits. 43 Multifocal lesion 13,47e53 Perilesional FAF pattern ¼ banded, diffuse (diffuse-trickling) 13, 26, 41, 44, 45, 52 Nonfoveal location; progression toward the periphery 1, 13, 28, 42, 43 Moderate evidence: Prior higher progression rate 42 Greater extent of abnormal hyperautofluorescence 70e72
Structural abnormalities at the junctional zone by OCT 27, 52, 73 Low evidence: Presence of vitreoretinal traction 59 Presence of outer retinal tubulations 52, 85 Moderate evidence: Reticular pseudodrusen presence 47, 53 Low evidence: Ellipsoid zone disruption 62, 81 Fellow eye High evidence: Bilateral GA 42, 78, 101 Higher progression rate in fellow eye 5, 42, 43, 100 Moderate evidence: CNV in the fellow eye 42, 101 Characteristics were rated as "high," "moderate," or "low" based on the available evidence to date supporting their association with GA progression. High: factor was identified as significantly associated with GA progression in multiple studies, including large prospective trials identified in Paracentral scotomas may substantially reduce the visual field, yet, depending on the extent of foveal sparing, patients may retain the ability to read individual letters and thus have relatively preserved BCVA. 7 Accordingly, there is not a robust correlation between BCVA changes and lesion enlargement. 13 Several alternative measures are being explored to capture the full visual deficit in GA, including microperimetry, low-luminance VA (LLVA), reading speed, and patient-reported outcomes.
Microperimetry
Microperimetry, which measures threshold light sensitivity at multiple points over the macula, can assess visual function loss associated with GA progression. Decreases in retinal sensitivity occur as GA progresses 105e107 and correlate with lesion enlargement over time. 108 The decrease in retinal sensitivity over the junctional zone can be abrupt, although nonatrophic regions in eyes with GA show reduced retinal sensitivity compared with eyes without evident atrophy. 109 Retinal sensitivity reductions are observed with increased autofluorescence in the junctional zone on FAF 110 and observations by OCT, including external limiting membrane loss, 111 RPE elevation, 112 innersegment ellipsoid band integrity loss, 112 and the presence of hyperreflective foci. 112 Clinical trials are beginning to incorporate microperimetry as a secondary endpoint to validate its utility to monitor GA progression. 16, 113, 114 Low-Luminance Visual Acuity Low-luminance VA measures visual function under reduced illumination. Deficits in LLVA are associated with higher GA lesion progression rates. 58 The difference between BCVA and LLVA, the "low luminance deficit," may predict subsequent VA loss. 7 
Reading Speed
Reading speed reflects the extent of the visual field, that is, whether the central visual field is preserved enough to read entire words or sentences versus individual letters. 7 Maximum reading rate correlates with GA area 115, 116 and worsens as GA progresses. 115 Low maximum reading rate ( 96 vs. 97e141 words per minute) at baseline was a significant risk factor for !3-line VA loss at 2 years. 7 Reading speed may serve as an important functional marker of GA progression and a potential predictor of future visual function loss.
Patient-Reported Outcomes
Questionnaire-based methods for measuring visual function have been applied to AMD, including the 25-item National Eye Institute Visual Function Questionnaire 117 and Activities of Daily Vision Scale. 118 These assess the patient's perception of how his/her visual deficit affects daily activities, including recognizing faces, driving, or reading newspapers. 119, 120 The Functional Reading Independence Index was developed for patients with GA; the Functional Reading Independence Index score decreased more in patients with greater lesion enlargement over 18 months. 121 The Functional Reading Independence Index and reading speed have received support from the European Medicines Agency to promote data sharing for eventual qualification as a novel methodology. 122 Future studies will need to assess how changes in patientreported outcomes correlate with GA progression.
Discussion
Geographic atrophy is an irreversible, progressive, bilateral, vision-threatening disorder, but how, when, and to what degree GA compromises visual function depends not only on the lesion size but also on the rate, location, and directionality of lesion enlargement (Fig 5) . In this review, we discussed factors associated with the rate and future location of GA lesion progression (Table 4) .
There is considerable interpatient variability in GA progression rates (Fig 2B) , whereas average rates from various studies fall into a fairly narrow range (Table 2) . 5,10,13,14,26,41e45,48e50,54e59,61e63 In addition, GA affects visual function in different ways and time scales. This review discussed factors that could inform an individual's prognosis, several of which were replicated in multiple cohorts: baseline lesion size, lesion location, multifocality, FAF patterns, and fellow-eye status (Table 4) . These identified prognostic factors are not necessarily independent and may describe different features of GA phenotypes. Identification of prognostic factors for disease severity and progression can inform models of disease progression 123 and may reflect differences in the pathophysiologic mechanisms of GA.
For the first time, several therapeutic agents for GA are in phase II and III clinical trials, including complement pathway inhibitors, agents targeting oxidative stress or inflammation, and stem cell therapies. Excepting early-stage stem cell trials, these investigational therapeutics aim to reduce the rate of, rather than halt or reverse, GA progression. Therefore, it is critical that eye care professionals and patients understand how different degrees of reduction in GA lesion enlargement will affect long-term visual function outcomes in order to manage expectations with respect to a patient's individual prognosis. In addition, it raises the clinical question regarding how early treatment, once available, should be initiated.
Currently, there is no systematic method for rating an individual's GA severity that incorporates various lesion characteristics, particularly those affecting visual function. For example, although lesion size is important, the degree of foveal involvement and impact of parafoveal lesions are key to relating GA lesions to visual function. Therefore, a standardized GA severity scale is necessary to assess a patient's disease severity at a given time and subsequently track disease progression. A validated scale could help standardize GA classification, predict progression, monitor progression over time, facilitate discussion with patients about disease progression and potential future treatments, and provide a holistic view of GA disease status.
In conclusion, many factors potentially prognostic for GA progression have been identified, yet a broader understanding of how these factors interact and relate to visual function, particularly for individual patients, is lacking. Standardized definitions and language surrounding GA are needed, including a multimodal definition of lesion borders and a GA severity measure encompassing more than lesion size; some of this is being addressed by the Classification of Atrophy Meetings initiatives. 15, 124 Further large-scale studies are needed to synthesize and unify the understanding of GA progression.
